219 related articles for article (PubMed ID: 23614566)
21. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
22. Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice.
Pan X; Kent R; Won KJ; Jeong H
Drug Metab Dispos; 2017 Apr; 45(4):346-352. PubMed ID: 28153841
[TBL] [Abstract][Full Text] [Related]
23. The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Qin X; Xie C; Hakenjos JM; MacKenzie KR; Boyd SR; Barzi M; Bissig KD; Young DW; Li F
Eur J Pharm Sci; 2023 Feb; 181():106358. PubMed ID: 36513193
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
27. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.
Mann A; Miksys S; Lee A; Mash DC; Tyndale RF
Neuropharmacology; 2008 Dec; 55(7):1147-55. PubMed ID: 18687346
[TBL] [Abstract][Full Text] [Related]
28. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.
Haertter S
Drug Metabol Drug Interact; 2013; 28(4):209-16. PubMed ID: 24088607
[TBL] [Abstract][Full Text] [Related]
29. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
Gelboin HV; Krausz KW; Shou M; Gonzalez FJ; Yang TJ
Pharmacogenetics; 1997 Dec; 7(6):469-77. PubMed ID: 9429232
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
[TBL] [Abstract][Full Text] [Related]
31. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
[TBL] [Abstract][Full Text] [Related]
32. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
[TBL] [Abstract][Full Text] [Related]
33. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
34. Effects of Fenofibrate on the Expression of Small Heterodimer Partner (SHP) and Cytochrome P450 (CYP) 2D6.
Kent R; Jeong H
Drug Metab Lett; 2017 Nov; 11(1):68-72. PubMed ID: 28403802
[TBL] [Abstract][Full Text] [Related]
35. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
37. Molecular cloning and expression of cytochrome P450 2D6 in the livers of domestic cats.
Komatsu T; Honda K; Kubota A; Kitazawa T; Hiraga T; Teraoka H
J Vet Med Sci; 2010 Dec; 72(12):1633-6. PubMed ID: 20661004
[TBL] [Abstract][Full Text] [Related]
38. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
39. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
[TBL] [Abstract][Full Text] [Related]
40. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]